Our immediate efforts are focused on the identification of converging pathways and therapeutic targets for Parkinson's disease. Parkinson's disease is the second most common neurodegenerative disease in the U.S. and is expected to afflict over 1 million U.S. patients in the next decade.

We strive to facilitate the development of targeted therapies for patients with different forms of Parkinsons's disease. Our pipeline is highly scalable, with the potential for numerous future applications to other neurodegenerative diseases and therapeutic areas.